VSL#3: Clinical Trials

13 trials of VSL#3, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 3 terminated, 3 unknown. 13 Phase 2, 5 Phase 3, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 213Completed 7, Terminated 3, Unknown 3
Phase 35Completed 3, Terminated 1, Unknown 1
Phase 13Completed 1, Terminated 1, Unknown 1

Follow VSL#3: new trials by email Literature Review of VSL#3 trials Research Report on VSL#3

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Maternal Probiotic Intervention to Improve Gut Health
Vivomixx, CapScanĀ® - Environmental Enteric Dysfunction, Stunting
Phase 2CompletedAga Khan University762023-08-092025-07-16
Ability of the Probiotic Vivomixx to Improve Environmental Enteropathy in Pregnant Women: a Proof of Concept Trial in Bangladesh, Pakistan, Senegal and Zambia
VSL#3, Capscan device, Placebo - Environmental Enteropathy
Phase 2UnknownTropical Gastroenterology & Nutrition Group (TROPGAN)762022-12-012022-11-08
Effect of VSL#3 on Bone Mineral Density in Postmenopausal Women
VSL#3, Placebo - Menopausal Osteoporosis
Phase 2TerminatedEmory University352017-10-012020-03-04
Probiotic (Visbiome) for Gulf War Illness
Placebo, Visbiome, VSL#3 - Gulf War Illness
Phase 2 / Phase 3UnknownAshok Tuteja602013-09-132017-12-13
Probiotic (VSL #3) for Gulf War Illness
VSL#3, Placebo - Gulf War Illness
Phase 2 / Phase 3TerminatedUniversity of Utah292013-09-012018-10-26
Secondary Prophylaxis of Hepatic Encephalopathy With a Probiotic Preparation
VSL#3, Placebo - Hepatic Encephalopathy
Phase 2 / Phase 3CompletedCD Pharma India Pvt. Ltd.1302010-04-012013-12-30
Probiotics for the Prevention of Antibiotics Associated Diarrhoea and Clostridium Difficile Associated Diarrhoea
VSL#3, Placebo - Diarrhoea
Phase 2 / Phase 3CompletedNational Health Service, United Kingdom2312010-04-012013-04-26
The Effect of Probiotics (VSL) on Portal Hypertension
Probiotic - Portal Hypertension
Phase 1 / Phase 2CompletedUniversity of Alberta182009-12-012012-01-20
Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life
VSL#3, Lactulose - Chronic Liver Disease, Hepatic Encephalopathy
Phase 2 / Phase 3CompletedCD Pharma India Pvt. Ltd.1202009-10-012013-06-04
A Pilot Trial to Determine the Efficacy of VSL#3 for Reducing Colonization by VRE
VSL#3, sugar pill (placebo) - Anti-biotic Resistance
Phase 2CompletedUniversity of Wisconsin, Madison902008-10-012015-10-08
Probiotics for Eradication of Carbapenem Resistant Klebsiella Pneumonia
VSL#3, Polyethylene glycol - Anti-Biotic Resistance, Klebsiella Pneumoniae
Phase 1 / Phase 2UnknownHadassah Medical Organization602008-09-012008-07-25
Safety of VSL#3 in Adult Asthmatics
VSL#3, VSL#3 or placebo - Asthma
Phase 1 / Phase 2TerminatedUniversity of Maryland, Baltimore32007-02-012023-04-20
Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC)
VSL#3, Placebo - Hirschsprung Disease
Phase 2CompletedUniversity of Michigan622006-09-012016-07-19

Conditions studied

Hepatic Encephalopathy (2)  ·  Irritable Bowel Syndrome (2)  ·  Asthma (1)  ·  Diarrhea (1)  ·  End Stage Liver Disease (1)  ·  Enterocolitis (1)  ·  Fibrosis (1)  ·  Growth Disorders (1)  ·  Hirschsprung Disease (1)  ·  Hypertension, Portal (1)  ·  Infections (1)  ·  Osteoporosis, Postmenopausal (1)

Sponsors

CD Pharma India Pvt. Ltd. (2)  ·  Aga Khan University (1)  ·  Ashok Tuteja (1)  ·  Emory University (1)  ·  Hadassah Medical Organization (1)  ·  National Health Service, United Kingdom (1)  ·  Tropical Gastroenterology & Nutrition Group (TROPGAN) (1)  ·  University of Alberta (1)  ·  University of Maryland, Baltimore (1)  ·  University of Michigan (1)  ·  University of Utah (1)  ·  University of Wisconsin, Madison (1)

Countries

United States (6)  ·  India (2)  ·  Pakistan (2)  ·  Bangladesh (1)  ·  Canada (1)  ·  Israel (1)  ·  Senegal (1)  ·  United Kingdom (1)  ·  Zambia (1)

Top investigators

Alessio Fasano, M. D. (1)  ·  Asad Ali, Dr (1)  ·  Asad Ali, MPH (1)  ·  Ashok Tuteja, MD, MPH (1)  ·  Daniel H Teitelbaum, MD (1)  ·  Fyezah Jehan, Dr (1)  ·  Maya Margalit, MD (1)  ·  Nasia Safdar, MD, MS (1)  ·  Neil Haslam (1)  ·  Paul Kelly, Dr (1)  ·  Puneeta Tandon, MD, FRCPC, MSc (1)  ·  Radha K Dhiman, MD,DM,MNAMS (1)  ·  Roberto Pacifici (1)  ·  Tahmeed Ahmed, Dr (1)  ·  Vince Bain, MD, FRCPC (1)

Results publications

PMID 23331802, PMID 23618760, PMID 25450083, PMID 27187907, PMID 31325468, PMID 34712928

NIH funding

R21AT004089 (1)